CO2022003888A2 - Sistemas y métodos de uso y regeneración de cromatografía - Google Patents

Sistemas y métodos de uso y regeneración de cromatografía

Info

Publication number
CO2022003888A2
CO2022003888A2 CONC2022/0003888A CO2022003888A CO2022003888A2 CO 2022003888 A2 CO2022003888 A2 CO 2022003888A2 CO 2022003888 A CO2022003888 A CO 2022003888A CO 2022003888 A2 CO2022003888 A2 CO 2022003888A2
Authority
CO
Colombia
Prior art keywords
alkaline solution
hydrophobic interaction
regeneration
chromatography
systems
Prior art date
Application number
CONC2022/0003888A
Other languages
English (en)
Inventor
John Mattila
James Reilly
Robert Stairs
Samantha Wadsworth
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2022003888A2 publication Critical patent/CO2022003888A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/40—Flow patterns using back flushing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/34—Regenerating or reactivating
    • B01J20/345—Regenerating or reactivating using a particular desorbing compound or mixture
    • B01J20/3475—Regenerating or reactivating using a particular desorbing compound or mixture in the liquid phase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00—Aspects relating to sorbent materials
    • B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/58—Use in a single column

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Aspectos de la presente divulgación se refieren a un método de regeneración de una columna de cromatografía de interacción hidrofóbica a la que se ha aplicado una masa de carga, comprendiendo el método pasar uno o más volúmenes de columna de una solución alcalina a través de medios de interacción hidrofóbica dentro de la columna, donde la solución alcalina presenta un pH de entre aproximadamente 10 y aproximadamente 14, y una conductividad de entre 0,5 mS/cm y aproximadamente 10 mS/cm, donde se elimina el material unido a los medios de interacción hidrofóbica. En algunos casos, la solución alcalina puede incluir hidróxido de sodio a una concentración de entre, por ejemplo, aproximadamente 0,1 mM y 10 mM.
CONC2022/0003888A 2019-09-24 2022-03-30 Sistemas y métodos de uso y regeneración de cromatografía CO2022003888A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905033P 2019-09-24 2019-09-24
US202062958899P 2020-01-09 2020-01-09
PCT/US2020/052243 WO2021061790A1 (en) 2019-09-24 2020-09-23 Systems and methods for chromatography use and regeneration

Publications (1)

Publication Number Publication Date
CO2022003888A2 true CO2022003888A2 (es) 2022-04-19

Family

ID=72896066

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0003888A CO2022003888A2 (es) 2019-09-24 2022-03-30 Sistemas y métodos de uso y regeneración de cromatografía

Country Status (13)

Country Link
US (1) US20220323937A1 (es)
EP (1) EP4034870A1 (es)
JP (1) JP2022548394A (es)
KR (1) KR20220066393A (es)
CN (1) CN114667450A (es)
AU (1) AU2020352547A1 (es)
BR (1) BR112022004885A2 (es)
CA (2) CA3150234C (es)
CL (1) CL2023003544A1 (es)
CO (1) CO2022003888A2 (es)
IL (1) IL291020A (es)
MX (1) MX2022003438A (es)
WO (1) WO2021061790A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023191827A1 (en) * 2022-03-28 2023-10-05 President And Fellows Of Harvard College High efficiency purification of divergent aav serotypes using aavx affinity chromatography
WO2024102939A1 (en) * 2022-11-09 2024-05-16 Genzyme Corporation Composition and methods for cleaning

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101809037B (zh) 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
EA028945B1 (ru) 2010-10-06 2018-01-31 Ридженерон Фармасьютикалз, Инк. СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
SG186552A1 (en) * 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
LT2780368T (lt) 2011-11-14 2018-03-12 Regeneron Pharmaceuticals, Inc. Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
US9067990B2 (en) * 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
JP6602765B2 (ja) * 2013-09-05 2019-11-06 ジェネンテック， インコーポレイテッド クロマトグラフィー再使用のための方法
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
MA39313B1 (fr) 2014-03-11 2018-12-31 Regeneron Pharma Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015256299C1 (en) 2014-05-05 2022-01-06 Regeneron Pharmaceuticals, Inc. Humanized C5 and C3 animals
KR20170062466A (ko) 2014-09-16 2017-06-07 리제너론 파마슈티칼스 인코포레이티드 항-글루카곤 항체 및 그것의 사용
AU2016233557B2 (en) * 2015-03-13 2021-06-24 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
CN104892734B (zh) * 2015-04-30 2019-09-13 中国科学院过程工程研究所 疏水作用层析提纯***灭活病毒抗原的方法
PL3500586T3 (pl) * 2016-10-17 2021-09-27 Enzene Biosciences Ltd. Sposób ciągły zmniejszania heterogeniczności białka terapeutycznego

Also Published As

Publication number Publication date
MX2022003438A (es) 2022-04-19
CL2023003544A1 (es) 2024-04-26
CA3216345A1 (en) 2021-04-01
CN114667450A (zh) 2022-06-24
IL291020A (en) 2022-05-01
BR112022004885A2 (pt) 2022-06-07
JP2022548394A (ja) 2022-11-18
EP4034870A1 (en) 2022-08-03
KR20220066393A (ko) 2022-05-24
CA3150234A1 (en) 2021-04-01
AU2020352547A1 (en) 2022-03-31
CA3150234C (en) 2023-12-12
WO2021061790A1 (en) 2021-04-01
US20220323937A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CL2023003544A1 (es) Sistemas y métodos de uso y regeneración de cromatografía
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
ES2162621T3 (es) Dispositivo y procedimiento para detectar analitos.
ES2045132T3 (es) Sensor de dioxido de carbono.
DE60303072D1 (de) Reaktionslösung für Tintenstrahldruckaufzeichnung, Vorrichtung und Tintenstrahlaufzeichnungsverfahren, die diese Lösung verwenden
CR8997A (es) Produccion de polipeptidos
DK0431456T3 (da) Anvendelse af et tungtopløseligt salt af en heteropolysyre til bestemmelse af en analyt, tilsvarende fremgangsmåde til bestemmelsen samt hertil egnet middel
SE9801287D0 (sv) Incorporation of active substances in carrier matrixes
ATE227337T1 (de) Trenn- und nachweisverfahren für spermatozoide
ES2125435T3 (es) Sistema conservador destinado para soluciones para lentes de contacto.
BR0313739A (pt) Método para minimizar a possibilidade de resultados falso-positivos e falso-negativos na detecção de pequenas quantidades de lìquido amniótico em secreção vaginal e dispositivo para realizar o método
BR0000068A (pt) Sistema e método para iniciar a operação de um sistema de computador
BRPI0414270A (pt) dispositivo de remoção de fluxo contìnuo e sistema utilizando o dito dispositivo
DK90683D0 (da) Fremgangsmade til udvinding af insulin fra et insulin-protaminkompleks
AR011557A1 (es) Un medio de cultivo y metodos para detectar estafilococos
DK1329461T3 (da) Fremgangsmåde til fjernelse af humane serum-albumin-polymerer
ES2179500T3 (es) Recipiente para tinta configurado para uso con un dispositivo de impresion que tiene un sistema detector del agotamiento de la tinta.
ATE534031T1 (de) Verfahren und vorrichtung für die chemische regenerierung mit verschiebung
AR063751A1 (es) Metodos para evaluar las velocidades de difusion de sistemas de administracion de farmacos oculares
FR2253615A1 (es)
JPS52129582A (en) Flaw detector
DE69221153T2 (de) Kationselektive Elektroden
ES2077357T3 (es) Separacion de particulas de sulfuro de hierro a partir de soluciones de alcanolaminas.
AR047461A1 (es) Formacion, purificacion y uso de n-formilolanzapina
UY25071A1 (es) Composiciones solubilizadas de sertralina